Drugs / CINTIRORGON
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03396497 | Aug 2018 → Oct 2019 | non-small cell lung carcinoma | Lycera Corp. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02929862 | Dec 2016 → May 2019 | cancer | Lycera Corp. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CINTIRORGON | ChEMBL registry synonym — accepted as the source's own label CHEMBL4472508 ↗ |
| Known as | LYC-55716 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02929862 ↗ |
| Action | Activate | “RORγ agonist” NCT02929862 ↗ |
| Modality | Small molecule | — CHEMBL4472508 ↗ |
| Route | Oral | “increasing doses of oral 55716 given BID” NCT02929862 ↗ |